Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026)
Neurocrine Biosciences' Research & Development was $326.7 million in Q2 2026, up 33.7% from $244.3 million a year earlier and up 10.3% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' Research & Development was $1.13 billion through Jun 30, 2026, up 27.4% year-over-year; for FY2025, it was $1.02 billion, up 38.9% from FY2024.
- Research & Development has now increased for eight consecutive years, with a five-year compound annual growth rate of 29.9% (FY2020 to FY2025).
- In earlier years, Research & Development was $731.1 million in FY2024 (+29.4%), $565 million in FY2023 (+21.8%), $463.8 million in FY2022 (+41.4%) and $328.1 million in FY2021 (+19.3%).
- The Q2 2026 figure marks the highest quarterly Research & Development in data going back to Q2 2010.
- Compared with a year earlier, Research & Development has increased for 20 straight quarters, with growth averaging 34.8% over the last eight quarters.
- Over the past five years, the year-over-year growth in Research & Development ranged from 7.3% (Q2 2023) to 81.7% (Q2 2022).
- Per Business Quant data, NBIX's Research & Development in the three quarters before Q2 2026 was $296.2 million (Q1 2026), $258.2 million (Q4 2025) and $250 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 326.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 326.70 Mn |
| Mar 31, 2026 | 296.20 Mn |
| Dec 31, 2025 | 258.20 Mn |
| Sep 30, 2025 | 250.00 Mn |
| Jun 30, 2025 | 244.30 Mn |
| Mar 31, 2025 | 263.20 Mn |
| Dec 31, 2024 | 185.60 Mn |
| Sep 30, 2024 | 195.00 Mn |
| Jun 30, 2024 | 191.10 Mn |
| Mar 31, 2024 | 159.40 Mn |
| Dec 31, 2023 | 137.50 Mn |
| Sep 30, 2023 | 142.20 Mn |
| Jun 30, 2023 | 145.80 Mn |
| Mar 31, 2023 | 139.50 Mn |
| Dec 31, 2022 | 118.00 Mn |
| Sep 30, 2022 | 107.70 Mn |
| Jun 30, 2022 | 135.90 Mn |
| Mar 31, 2022 | 102.20 Mn |
| Dec 31, 2021 | 87.40 Mn |
| Sep 30, 2021 | 92.70 Mn |
API Access
Neurocrine Biosciences Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();